keyword
https://read.qxmd.com/read/38417904/emedastine-inhibits-th1-and-th2-cell-differentiation-mediated-by-mast-cells
#21
JOURNAL ARTICLE
Katsuhiko Matsui, Akari Kuroki, Aya Morishima
We have previously clarified that emedastine, a second-generation antihistamine drug, inhibits T helper 1(Th1)/Th2 cell differentiation mediated by Langerhans cells (LCs). In addition, although we have recently found that mast cells also function as antigen-presenting cells (APCs) and induce Th1/Th2 cell differentiation, any influence of emedastine on this function remained unclear. Here we investigated the influence of emedastine on Th1/Th2 cell differentiation via mast cells. Mast cells were obtained by long-term culture of murine splenocytes in medium supplemented with tumor necrosis factor (TNF)-α...
2024: Biological & Pharmaceutical Bulletin
https://read.qxmd.com/read/38417541/topical-ruxolitinib-in-the-treatment-of-necrobiosis-lipoidica-a-prospective-open-label-study
#22
JOURNAL ARTICLE
Angelina S Hwang, Jacob A Kechter, Xing Li, Alysia Hughes, Kevin J Severson, Blake Boudreaux, Puneet Bhullar, Shams Nassir, Miranda Yousif, Nan Zhang, Richard J Butterfield, Steven Nelson, Xianying Xing, Lam C Tsoi, Samantha Zunich, Aleksandar Sekulic, Mark Pittelkow, Johann E Gudjonsson, Aaron Mangold
Necrobiosis Lipoidica (NL) is a rare granulomatous disease. There are few effective treatments for NL. We sought to investigate the efficacy and safety of the JAK 1/2 inhibitor, ruxolitnib, in the treatment of NL and identify biomarkers associated with disease and treatment response. We conducted an open-label, phase 2 study of ruxolitinib in 12 patients with NL. We performed transcriptomic analysis of tissue samples pre- and post-treatment. At week 12, the mean NL lesion score decreased by 58.2% (SD 28.7%, P=0...
February 26, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38380373/interferons-in-the-treatment-of-myeloproliferative-neoplasms
#23
REVIEW
Pankit Vachhani, John Mascarenhas, Prithviraj Bose, Gabriela Hobbs, Abdulraheem Yacoub, Jeanne M Palmer, Aaron T Gerds, Lucia Masarova, Andrew T Kuykendall, Raajit K Rampal, Ruben Mesa, Srdan Verstovsek
Interferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current therapeutic landscape, pegylated interferons are recommended for use in the treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis...
2024: Therapeutic Advances in Hematology
https://read.qxmd.com/read/38368838/immunomodulatory-and-anti-angiogenesis-effects-of-excavatolide-b-and-its-derivatives-in-alleviating-atopic-dermatitis
#24
JOURNAL ARTICLE
Hsiu-Wen Chen, Feng-Cheng Liu, Hsiao-Mei Kuo, Shih-Hsuan Tang, Guang-Hao Niu, Mingzi M Zhang, Lun Kelvin Tsou, Ping-Jyun Sung, Zhi-Hong Wen
Atopic dermatitis (AD) is a chronic inflammatory skin condition primarily driven by T helper 2 (Th2) cytokines, resulting in skin barrier defects, angiogenesis, and inflammatory responses. The marine natural product excavatolide B (EXCB), isolated from the Formosan Gorgonian coral Briareum stechei, exhibits anti-inflammatory and analgesic properties. To enhance solubility, EXCB is chemically modified into the derivatives EXCB-61 salt and EXCB-79. The study aims to investigate the therapeutic effects of these compounds on dinitrochlorbenzene (DNCB)-induced skin damage and to elucidate the underlying anti-inflammatory and anti-angiogenesis mechanism...
February 17, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38352458/interferon-%C3%AE-signaling-in-eosinophilic-esophagitis-has-implications-for-epithelial-barrier-function-and-programmed-cell-death
#25
Megha Lal, Caitlin M Burk, Ravi Gautam, Zoe Mrozek, Tina Trachsel, Jarad Beers, Margaret C Carroll, Duncan M Morgan, Amanda B Muir, Wayne G Shreffler, Melanie A Ruffner
OBJECTIVE: Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disorder characterized by eosinophil-rich mucosal inflammation and tissue remodeling. Transcriptional profiling of esophageal biopsies has previously revealed upregulation of type I and II interferon (IFN) response genes. We aim to unravel interactions between immune and epithelial cells and examine functional significance in esophageal epithelial cells.Design We investigated epithelial gene expression from EoE patients using single-cell RNA sequencing and a confirmatory bulk RNA-sequencing experiment of isolated epithelial cells...
January 30, 2024: bioRxiv
https://read.qxmd.com/read/38343470/a-clearer-vision-insights-into-juvenile-idiopathic-arthritis-associated-uveitis
#26
JOURNAL ARTICLE
Ihda M Bani Khalaf, Hritvik Jain, Nilofar M Vora, Noor Ul Ain, Farhan Murtaza, Muskaan Doulat Ram, Avinash Nankani, Jatin Motwani
The aim of this narrative review is to synthesize existing evidence-based knowledge on juvenile idiopathic arthritis-associated uveitis (JIA-U). We highlight epidemiology, pathophysiology, causes and genetics, risk factors, clinical features, diagnosis and screening, laboratory biomarkers, treatment options, trials with recent advances, and research challenges pertaining to JIA-U. The prevalence of JIA-U varies with different JIA subtypes, most frequently associated with the oligoarticular subtype. The risk factors involved in the development of JIA-U include younger age, antinuclear antibody (ANA) positivity, and the oligoarticular subtype of JIA, along with some specific major histocompatibility complex genes...
2024: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/38296759/therapeutic-implications-of-the-interplay-between-interferons-and-er-in-breast-cancer
#27
JOURNAL ARTICLE
Nataša Todorović-Raković, Jonathan R Whitfield
The involvement of interferons (IFNs) in various diseases, including breast cancer, has sparked controversy due to their diverse roles in immunity and significant impact on pathological mechanisms. In the context of breast cancer, the heightened expression of endogenous IFNs has been linked to anti-tumor activity and a favorable prognosis for patients. Within the tumor tissue and microenvironment, IFNs initiate a cascade of molecular events involving numerous factors, which can lead to either cooperative or repressive interactions...
January 5, 2024: Cytokine & Growth Factor Reviews
https://read.qxmd.com/read/38291045/effect-of-interferon-therapy-on-quality-of-life-in-patients-with-chronic-hepatitis-b
#28
JOURNAL ARTICLE
Mengdi Zhang, Meijuan Wan, Wen Wang, Shumei Lin, Xi Zhang
Interferon therapy is the most effective treatment for achieving clinical cure in chronic hepatitis B (CHB) patients. However, the treatment outcomes of interferon therapy are uncertain, multiple side effects can occur during treatment, and the treatment is expensive. Although these characteristics may affect patients' quality of life, research examining this topic is limited. We used a cross-sectional design to examine 100 CHB patients receiving interferon, 100 receiving nucleoside/nucleotide analogues, and 87 receiving non-antiviral treatment...
January 30, 2024: Scientific Reports
https://read.qxmd.com/read/38238848/a-bibliometric-analysis-of-m6a-methylation-in-viral-infection-from-2000-to-2022
#29
JOURNAL ARTICLE
Xing Tao, Gang Wang, Wudi Wei, Jinming Su, Xiu Chen, Minjuan Shi, Yinlu Liao, Tongxue Qin, Yuting Wu, Beibei Lu, Hao Liang, Li Ye, Junjun Jiang
BACKGROUND: N6-methyladenosine (m6A) methylation has become an active research area in viral infection, while little bibliometric analysis has been performed. In this study, we aim to visualize hotspots and trends using bibliometric analysis to provide a comprehensive and objective overview of the current research dynamics in this field. METHODS: The data related to m6A methylation in viral infection were obtained through the Web of Science Core Collection form 2000 to 2022...
January 18, 2024: Virology Journal
https://read.qxmd.com/read/38236065/ocular-surface-squamous-neoplasia-changes-in-the-standard-of-care-2003-to-2022
#30
JOURNAL ARTICLE
Jason A Greenfield, Adam K Cohen, Anat Galor, James Chodosh, Donald Stone, Carol L Karp
PURPOSE: The aim of this review was to elucidate treatment preferences for ocular surface squamous neoplasia and to examine the changes in treatment modalities over the past 2 decades. METHODS: An electronic survey was distributed to members of The Cornea Society, Ocular Microbiology and Immunology Group, and 4 international corneal specialist listservs. Questions examined medical and surgical treatment preferences, and results were compared with surveys administered in 2003 and 2012...
January 18, 2024: Cornea
https://read.qxmd.com/read/38224725/evaluation-of-combination-of-ala-pdt-and-interferon-for-cervical-low-grade-squamous-intraepithelial-lesion-lsil
#31
JOURNAL ARTICLE
Sijing Li, Min Zhao, Ming Luo, Jin Wu, Zhaoning Duan, Xiaoling Huang, Shan Lu, Qiao Zu, Qun Xiao, Jia Ying
BACKGROUND: Cervical LSIL is a precancerous disease which requires regular follow-up. High risk patients need active interventions. Interferon and topical PDT have been used in the treatment of cervical LSIL. The aim of this study was to evaluate the combination use of topical PDT and interferon in the treatment of cervical LSIL. MATERIALS AND METHODS: A prospective study was carried out involving 159 women with cervical LSIL and high risk human papillomaviruses (hr-HPV) infection...
January 13, 2024: Photodiagnosis and Photodynamic Therapy
https://read.qxmd.com/read/38174776/immunomodulators-and-immunosuppressants-for-relapsing-remitting-multiple-sclerosis-a-network-meta-analysis
#32
REVIEW
Marien Gonzalez-Lorenzo, Ben Ridley, Silvia Minozzi, Cinzia Del Giovane, Guy Peryer, Thomas Piggott, Matteo Foschi, Graziella Filippini, Irene Tramacere, Elisa Baldin, Francesco Nonino
BACKGROUND: Different therapeutic strategies are available for the treatment of people with relapsing-remitting multiple sclerosis (RRMS), including immunomodulators, immunosuppressants and biological agents. Although each one of these therapies reduces relapse frequency and slows disability accumulation compared to no treatment, their relative benefit remains unclear. This is an update of a Cochrane review published in 2015. OBJECTIVES: To compare the efficacy and safety, through network meta-analysis, of interferon beta-1b, interferon beta-1a, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, pegylated interferon beta-1a, daclizumab, laquinimod, azathioprine, immunoglobulins, cladribine, cyclophosphamide, diroximel fumarate, fludarabine, interferon beta 1-a and beta 1-b, leflunomide, methotrexate, minocycline, mycophenolate mofetil, ofatumumab, ozanimod, ponesimod, rituximab, siponimod and steroids for the treatment of people with RRMS...
January 4, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38172219/evodiae-fructus-extract-suppresses-inflammatory-response-in-hacat-cells-and-improves-house-dust-mite-induced-atopic-dermatitis-in-nc-nga-mice
#33
JOURNAL ARTICLE
Seong Eun Jin, Chang-Seob Seo, Woo-Young Jeon, Yong Jin Oh, Hyeun-Kyoo Shin, Hye Gwang Jeong, Hyekyung Ha
This study was conducted to assess the effect of Evodiae Fructus 70% ethanol extract (EFE) on the pathology of atopic dermatitis using in vitro and in vivo models. The major compounds in EFE were identified by ultra-performance liquid chromatography with tandem mass spectrometry as rutaecarpine, evodiamine, evodol, dehydroevodiamine, limonin, synephrine, evocarpine, dihydroevocarpine, and hydroxyevodiamine. EFE significantly decreased chemokine levels in tumor necrosis factor-α/interferon-γ-stimulated HaCaT cells...
January 4, 2024: Scientific Reports
https://read.qxmd.com/read/38160866/the-therapeutic-efficacy-and-mechanism-action-of-si-cao-formula-in-the-treatment-of-psoriasis-a-pilot-clinical-investigation-and-animal-validation
#34
JOURNAL ARTICLE
Xinxin Wu, Qi Zheng, Fang Shen, Jiankun Song, Yue Luo, Xiaoya Fei, Wencheng Jiang, Shaoqiong Xie, Xin Ma, Le Kuai, Ruiping Wang, Xiaojie Ding, Miao Li, Ying Luo, Bin Li
ETHNOPHARMACOLOGICAL RELEVANCE: Psoriasis is a chronic inflammation and relapsing disease that affected approximately 100 million individuals worldwide. In previous clinical study, it was observed that the topical application of Si Cao Formula (SCF) ameliorated psoriasis skin lesions and reduced the recurrence rate of patients over a period of three months. However, the precise mechanism remains unclear. AIM OF THE STUDY: The objective of this study was to assess the effectiveness and safety of SCF in patients diagnosed with psoriasis and explore the molecular mechanisms that contribute to SCF's therapeutic efficacy in psoriasis treatment...
December 29, 2023: Journal of Ethnopharmacology
https://read.qxmd.com/read/38150467/circmorc3-encoded-novel-protein-negatively-regulates-antiviral-immunity-through-synergizing-with-host-gene-morc3
#35
JOURNAL ARTICLE
Linchao Wang, Weiwei Zheng, Xing Lv, Yanhong Song, Tianjun Xu
The protein-coding ability of circRNAs has recently been a hot topic, but the role of protein-coding circRNAs in antiviral innate immunity of teleost fish has rarely been reported. Here, we identified a novel circRNA, termed circMORC3, derived from Microrchidia 3 (MORC3) gene in Miichthys miiuy. circMORC3 can inhibit the expression of antiviral cytokines. In addition, circMORC3 encodes a novel peptide with a length of 84 amino acids termed MORC3-84aa. MORC3-84aa not only significantly inhibited TRIF-mediated activation of IRF3 and NF-κB signaling pathways, but also effectively suppressed the expression of antiviral cytokines triggered by RNA virus Siniperca chuatsi rhabdovirus (SCRV)...
December 27, 2023: PLoS Pathogens
https://read.qxmd.com/read/38048299/biohabana-2022-preventive-and-immunotherapeutic-strategies-against-covid-19-and-cancer-in-cuba
#36
JOURNAL ARTICLE
Iraldo Bello-Rivero, Tania Crombet-Ramos, Circe Mesa-Pardillo, Yanelys Morera-Díaz, Zaima Mazorra-Herrera, Dagmar Garcia-Rivera, Hugo Nodarse-Cuní, Francisco Hernández-Bernal, Verena Muzio-Gonzalez, Ana Aguilera-Barreto, Dania Vazquez-Blomquist, Maria Del Carmen Domínguez-Horta, Gerardo Guillen-Nieto
The convergence of life sciences with neurosciences, nanotechnology, data management, and engineering has caused a technological diversification of the biotechnology, pharmaceutical, and medical technology industries, including the phenomenon of digital transformation, which has given rise to the so-called Fourth Industrial Revolution (Industry 4.0). Confronting the COVID-19 pandemic revealed the outstanding response capacity of the scientific community and the biopharmaceutical industry, based on a multidisciplinary and interinstitutional approach that has achieved an unprecedented integration in the history of biomedical science...
December 4, 2023: Journal of Interferon & Cytokine Research
https://read.qxmd.com/read/38032059/adverse-effects-of-immunotherapies-for-multiple-sclerosis-a-network-meta-analysis
#37
REVIEW
Irene Tramacere, Gianni Virgili, Vittorio Perduca, Ersilia Lucenteforte, Maria Donata Benedetti, Matteo Capobussi, Greta Castellini, Serena Frau, Marien Gonzalez-Lorenzo, Robin Featherstone, Graziella Filippini
BACKGROUND: Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability after onset. Although it is accepted that immunotherapies for people with MS decrease disease activity, uncertainty regarding their relative safety remains. OBJECTIVES: To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through network meta-analyses (NMAs)...
November 30, 2023: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38017308/a-nanoinhibitor-targeting-cgas-sting-pathway-to-reverse-the-homeostatic-imbalance-of-inflammation-in-psoriasis
#38
JOURNAL ARTICLE
Zhibin Zhang, Dongtao Zhou, Zhun Li, Xiaowei Luan, Jingjing Yang, Shaochun Tang, Yujun Song
Psoriasis is a chronic skin inflammation characterized by dysregulated crosstalk between immune cells and keratinocytes. Here we show that the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a key regulator of psoriatic inflammation in a mouse model. Platinum-doped positively charged carbon dots (Pt-CDs) were designed to inhibit the cGAS-STING pathway. By inhibiting the cGAS-STING pathway with Pt-CDs, the secretion of proinflammatory cytokines in macrophages was reduced, and the proinflammatory cytokines-induced breakdown of immunological tolerance and overexpression of chemokines in keratinocytes was restored, which reversed the homeostatic imbalance through breaking these cytokines-mediated intercellular positive feedback loop...
November 28, 2023: Angewandte Chemie
https://read.qxmd.com/read/38001905/anifrolumab-for-moderate-and-severe-muco-cutaneous-lupus-erythematosus-a-monocentric-experience-and-review-of-the-current-literature
#39
JOURNAL ARTICLE
Giovanni Paolino, Giuseppe A Ramirez, Chiara Calabrese, Luca Moroni, Vittoria Giulia Bianchi, Enrica P Bozzolo, Santo Raffaele Mercuri, Lorenzo Dagna
Refractory cutaneous manifestations constitute a significant unmet need in patients with cutaneous lupus (CLE), even in the setting of systemic lupus erythematosus (SLE) with otherwise good control of inflammatory manifestations. Anifrolumab, an anti-interferon I receptor monoclonal antibody has recently been approved for serologically positive SLE with or without CLE, but real-life efficacy and safety data are currently limited. In addition, relatively limited evidence exists about the spectrum of cutaneous manifestations potentially benefitting from anifrolumab treatment and about the optimal clinimetrics to monitor treatment efficacy...
October 26, 2023: Biomedicines
https://read.qxmd.com/read/37989697/ethanol-extract-of-herpetospermum-caudigerum-wall-ameliorates-psoriasis-like-skin-inflammation-and-promotes-degradation-of-keratinocyte-derived-icam-1-and-cxcl9
#40
JOURNAL ARTICLE
Ya Zhong, Bo-Wen Zhang, Jin-Tao Li, Xin Zeng, Jun-Xia Pei, Ya-Mei Zhang, Yi-Xi Yang, Fu-Lun Li, Yu Deng, Qi Zhao
OBJECTIVE: To explore whether the ethanol extract of Herpetospermum caudigerum Wall (EHC), a Xizang medicinal plant traditionally used for treating liver diseases, can improve imiquimod-induced psoriasis-like skin inflammation. METHODS: Immunohistochemistry and immunofluorescence staining were used to determine the effects of topical EHC use in vivo on the skin pathology of imiquimod-induced psoriasis in mice. The protein levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and interleukin-17A (IL-17A) in mouse skin samples were examined using immunohistochemical staining...
November 11, 2023: Journal of Integrative Medicine
keyword
keyword
166663
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.